3D Printed Drugs Market, By Technology Outlook (Inkjet Printing, Zipdose Technology, Stereolithography), By Application (Orthopedic, Neurology, Dental, Others), By End-use (Hospitals & clinics, Research Laboratories, Others), By Region – Global Analysis Forecast Till 2030

The Global 3D Printed Drugs Market size was estimated at USD 72.02 Million in 2021 and is expected to hit around USD 269.74 Million growing at a compound annual growth rate (CAGR) of 15.8%.

Despite being created in 1986, 3D printing recently captured the public's interest. Over the past ten years, there have been less distinctions between science fiction and reality. It is also referred to as "additive manufacturing" and is used in various sectors, including the automotive, aerospace and defense, retail, and healthcare and medical fields.

A large part of this is the market for medicines printed in 3D. What was before costly and inaccessible is now considerably more affordable thanks to 3D printing. Hearing aids and even replacement bones are already produced using 3D printing and surgical materials that use 3D models to mend fractured or missing bones. Both titanium heels and skull implants for those with bone cancer have been created.

Market Dynamics

Drivers:

The sales of 3D-printed medicines are increasing for a number of reasons. A big advantage is how quickly they dissolve. Drugs are produced using powder bed inkjet technology. Similar to 3D printing for any other device, the components of the medicine are layered on top of one another.

For patients with dysphagia, this makes it easier to swallow the drugs and may be very helpful. Pharmaceuticals made specifically for each patient or the creation of therapeutic combinations could both advance more quickly thanks to 3D printing. They would be significantly more advantageous than batch-produced pharmaceuticals as these would be made specifically for the patient with his medical history in mind.

If 3D-printed medicines allow patients to customize the shape, colour, style, and even flavour of the tablet, children may be less reluctant to take prescribed medication! These are anticipated to be the industry's main propellants for 3D-printed medicines.

Restraints:

Every new technology will inevitably have some downsides, and identifying and preventing them can frequently be a battle against time. The market for 3D printed drugs requires creating a 3D design of the patient, their medical background, the required dosage, and other information.

Patients may be reluctant to provide their medical information for 3D printed pharmaceuticals in light of current problems concerning hacking and phishing of data stored online and in the cloud. Another issue could be incorrectly labeled blueprints, inaccurate descriptions, or doses that are stronger than stated.

As 3D printing spreads, it might be used to manufacture illegal drugs, making it harder for law enforcement to stop the burgeoning black market trade in them. Lack of regulation would be the main obstacle to 3D-printed medications being commercialized.

Key players:

• Aprecia

• Extend Biosciences

• Bioduro

• Affinity Therapeutics

• Osmotica Pharmaceuticals

• Aprecia Pharmaceuticals LLC

• GlaxoSmithKline Plc

• FabRx Ltd

• Hewlett Packard Caribe

• Merck

• Cycle Pharmaceuticals

• AstraZeneca

Market Segmentation:

3D Printed Drugs Market, By Technology

• Inkjet Printing

• Fused Deposition Modeling

• Stereolithography

• ZipDose Technology

3D Printed Drugs Market, By Application

• Orthopedic

• Neurology

• Dental

• Others

3D Printed Drugs Market, By End-use

• Hospitals & clinics

• Research Laboratories

• Others

3D Printed Drugs Market, By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa (MEA)

Regional Analysis:

In 2021, North America has an XX% share of the regional market, dominating it. This sizeable portion can be attributed to the region of North America's growing adoption of technology advancements, rising incidence of chronic diseases, outstanding domestic healthcare infrastructure, and substantial expenditure in R&D.

The Asia Pacific is predicted to have the quickest growth owing to considerable advancements made by China and Japan in the technological application of 3D-printed medication techniques. Aside from that, the development of clinical development frameworks, R&D, and healthcare infrastructure in developing nations like Australia and India has put the Asia Pacific 3D Printed Drugs market in a position to experience profitable prospects and growth throughout the projected period.

Scope of the Report:

User

Tab Content